A quiet heat-treatment specialist finds itself the object of a bidding contest
Shares in Bodycote, the Macclesfield-based thermal-processing group, closed at 923.00p on Wednesday 5 August 2026, a leap of 173.00p, or 23.07%, on the day (London Stock Exchange close; London South East data). The trigger was not a single event but a combination: fresh half-year numbers that showed margins climbing on aerospace and defence demand, and confirmation that two private-equity houses are circling the business barely two months after an earlier suitor walked away. For a stock that spent much of the past year in the FTSE 250's unglamorous middle, it was an emphatic re-rating.
Two suitors, one deadline
The decisive news came in a Rule 2.4 announcement. Bodycote confirmed it had received separate, conditional proposals from CVC Capital Partners and Veritas Capital. CVC's indicative terms amount to up to 915p per share (907.8p in cash plus the 7.2p interim dividend), while Veritas has floated up to 914p (906.8p cash plus the same dividend). Both value the equity at roughly £1.56bn. The board said it would be "minded to recommend unanimously" either proposal were a firm offer made on those terms, and both parties have been granted access to confirmatory due diligence.
The critical distinction for investors is that these remain possible offers, not firm ones, and certainly not agreed deals. Under the City Code, each suitor faces a "put up or shut up" deadline of 5.00pm on 2 September 2026, by which point they must either announce a firm intention to bid or walk away. Nothing is binding until then, and either party could yet lower its terms, attach conditions or withdraw entirely.
This is Bodycote's second brush with private equity this year. In May, Apollo Global Management approached the company with an all-cash proposal pitched at 885p per share, a move that briefly lifted the stock to a multi-year high. That interest evaporated on 5 June, when Apollo issued a Rule 2.8 statement confirming it did not intend to make a firm offer; the shares fell as much as 12% that day, the sharpest faller in the FTSE 250. Under takeover rules Apollo is generally barred from returning for six months, though a firm bid from a third party could release it from that restriction, a nuance worth keeping in mind given the stock now trades above both current indicative prices.
What Bodycote actually does
Bodycote (LSE:BOY) is the world's largest provider of outsourced heat treatment and specialist thermal processing. In plain terms, manufacturers send it metal components, turbine blades, landing-gear parts, engine casings, medical implants and the group hardens, strengthens or coats them using controlled heating, hot isostatic pressing and surface technologies before returning them. It is an asset-heavy, energy-intensive business with a network of plants across the Americas, Europe and Asia, and its fortunes track the capital-spending and production cycles of its end markets.
The company now reports through two divisions. Specialist Technologies, the higher-margin arm covering hot isostatic pressing, surface treatments and other proprietary processes, generated £121.2m of revenue in the first half at a 26.1% operating margin. The larger Precision Heat Treatment division contributed £250.8m at a 15.0% margin. That structure explains much of the investment case: the more differentiated the process, the harder it is to replicate and the better the returns.
The numbers behind the re-rating
The interim results, published on 27 July 2026 for the six months to 30 June, gave the bidders something to chew on. Group revenue rose 3.3% to £381.2m, with organic growth of 6.5% and "core" organic growth, stripping out declining lines, of 9.6%. The mix mattered more than the headline: aerospace and defence revenue jumped around 25%, industrial gas turbines rose about 11% and medical roughly 15%, while automotive slipped some 4%, a familiar pattern of defence strength offsetting consumer-facing weakness.
Adjusted operating profit climbed 10.7% to £61.0m and the adjusted operating margin widened 110 basis points to 16.0%, evidence that pricing discipline and the richer aerospace mix are feeding through. Statutory operating profit was £45.6m, the gap reflecting amortisation and one-off items, including £0.6m of costs tied to the earlier Apollo approach. Adjusted basic earnings per share reached 25.2p, up from 21.3p, and the interim dividend was lifted 4.3% to 7.2p.
Cash and the balance sheet are the less flattering side of the ledger. First-half free cash flow eased to £14.5m from £18.0m a year earlier, and net debt excluding lease liabilities rose to £135.2m from £104.8m at the end of December 2025, reflecting capital investment and working-capital timing. Neither figure is alarming for a business of this scale, but it is a reminder that thermal processing swallows capital.
The bull case
Supporters will point to the obvious: two credible financial buyers competing for the same asset, with the share price sitting above both indicative levels, suggests the market anticipates either a firm offer or a sweetened one. The operational backdrop is supportive, with structural growth in aerospace, defence and power generation, high barriers to entry, and a widening margin. For long-suffering holders, past performance offers no guarantee, but the strategic logic of a private-equity owner willing to invest through the cycle is easy to grasp.
The bear case and the risks
The counterweights are equally clear. Possible offers are not firm offers, and Apollo's abrupt exit in June is a live reminder that indicative interest can vanish. If both CVC and Veritas were to withdraw by 2 September, the shares would likely give back a large slice of Wednesday's gain, since 923p bakes in a bid premium that fundamentals alone may not sustain. The automotive softness, the dip in free cash flow and the rise in net debt are cyclical vulnerabilities. And a stock trading above the highest indicative price carries its own risk: buyers hoping for a knockout bump could be disappointed if the winning suitor simply firms up at, or below, 915p.
What to watch next
The 2 September put-up-or-shut-up deadline is the pivotal date. Investors should watch for a Rule 2.7 firm-offer announcement from either party, any counter-move that might free Apollo from its lock-out, and the board's formal recommendation.
Conclusion
Bodycote's 23% surge reflects genuine corporate action layered on improving fundamentals, not hype. Yet the reignited interest comes from CVC and Veritas, not Apollo, and remains at the possible-offer stage. Whether shareholders bank a premium or watch it evaporate now hinges on a single September deadline. This is neither a guaranteed recovery nor a done deal, and the coming weeks will decide which.






Please wait processing your request...